Teva Pharma Ownership
| TEVA Stock | USD 16.24 0.05 0.31% |
Shares in Circulation | First Issued 1985-09-30 | Previous Quarter 1.1 B | Current Value 1.2 B | Avarage Shares Outstanding 719.4 M | Quarterly Volatility 257.2 M |
Some institutional investors establish a significant position in stocks such as Teva Pharma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Teva Pharma, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Teva |
Teva Stock Ownership Analysis
About 60.0% of the company shares are owned by institutional investors. The book value of Teva Pharma was at this time reported as 4.74. The company has Price/Earnings To Growth (PEG) ratio of 0.98. Teva Pharma Industries recorded a loss per share of 1.43. The entity last dividend was issued on the 27th of November 2017. The firm had 2:1 split on the 1st of July 2004. Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel. Teva Pharmaceutical is traded on New York Stock Exchange in the United States. To find out more about Teva Pharma Industries contact Kare Schultz at 972 3 914 8213 or learn more at https://www.tevapharm.com.Besides selling stocks to institutional investors, Teva Pharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Teva Pharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Teva Pharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Teva Pharma Quarterly Liabilities And Stockholders Equity |
|
Teva Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Teva Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Teva Pharma Industries backward and forwards among themselves. Teva Pharma's institutional investor refers to the entity that pools money to purchase Teva Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Pointstate Capital Lp | 2024-12-31 | 13.5 M | |
| Geode Capital Management, Llc | 2024-12-31 | 9.3 M | |
| Australiansuper Pty Ltd | 2024-12-31 | 9.2 M | |
| Duquesne Family Office Llc | 2024-12-31 | 9 M | |
| Slate Path Capital Lp | 2024-12-31 | 8.5 M | |
| Glenview Capital Management Llc | 2024-12-31 | 8.5 M | |
| Arrowstreet Capital Limited Partnership | 2024-12-31 | 7 M | |
| Renaissance Technologies Corp | 2024-12-31 | 7 M | |
| Hhg Plc | 2024-12-31 | 6.7 M | |
| Fmr Inc | 2024-12-31 | 82 M | |
| Blackrock Inc | 2024-12-31 | 50.6 M |
Teva Pharma Industries Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Teva Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Teva Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Teva Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Teva Pharma Outstanding Bonds
Teva Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Teva Pharma Industries uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Teva bonds can be classified according to their maturity, which is the date when Teva Pharma Industries has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| TEVA 5125 09 MAY 29 Corp BondUS88167AAQ40 | View | |
| TEVA 475 09 MAY 27 Corp BondUS88167AAP66 | View | |
| TEVA 8125 15 SEP 31 Corp BondUS88167AAR23 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| TEXACO CAP INC Corp BondUS881685BB68 | View |
Teva Pharma Corporate Filings
F4 | 7th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 12th of February 2025 Other Reports | ViewVerify | |
ASR | 7th of February 2025 Automatic Shelf Registration Statement under Rule 415 filed with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
10K | 5th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (1.43) | Revenue Per Share | Quarterly Revenue Growth (0.05) | Return On Assets |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.